Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses

Vaccine

Volumn 26, Issue 42, 2008, Pages 5400-5406

  Gordon, Stephen B ^a,b,c   Malamba, Rose ^b   Mthunthama, Neema ^b   Jarman, Elizabeth R ^b   Jambo, Kondwani ^a,b   Jere, Khuzwayo ^b   Zijlstra, Eduard E ^c   Molyneux, Malcolm E ^a,b   Dennis, John ^d   French, Neil ^b,e  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF MALAWI   (Malawi)

^d UNIVERSITY OF CALGARY   (Canada)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Bronchoalveolar lavage; Immunoglobulin; Inhaled pneumococcal vaccine; Lung; Mucosa; Pneumonia; Polysaccharide; Streptococcus pneumoniae

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE;

ABDOMINAL DISTENSION; ADULT; ANTIBODY RESPONSE; ARTICLE; BRONCHOSCOPY; CHILL; DIARRHEA; DIZZINESS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; LUNG LAVAGE; MALAISE; MALE; MUCOSAL IMMUNITY; NEBULIZATION; NORMAL HUMAN; PRIORITY JOURNAL; SAMPLE SIZE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VOLUNTEER; XEROSTOMIA;

ADMINISTRATION, INHALATION; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BACTERIAL CAPSULES; BRONCHOALVEOLAR LAVAGE FLUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 51349139831     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.082     Document Type: Article

References (48)

1. Brown P.D., and Lerner S.A. Community-acquired pneumonia. Lancet 352 October (9136) (1998) 1295-1302
2. Butler J.C. Epidemiology of pneumococcal disease. In: Tuomanen E.I., Mitchell T.J., Morrison D.A., and Spratt B.G. (Eds). The pneumococcus. 1st ed. (2004), ASM Press, Washington, DC 148-168
3. Scott J.A., Hall A.J., Muyodi C., Lowe B., Ross M., Chohan B., et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 355 April (9211) (2000) 1225-1230
4. Gordon S.B., Walsh A.L., Chaponda M., Gordon M.A., Soko D., Mbwvinji M., et al. Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. Clin Infect Dis 31 July (1) (2000) 53-57
5. Gilks C.F., Ojoo S.A., Ojoo J.C., Brindle R.J., Paul J., Batchelor B.I., et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 347 (1996) 718-723
6. Gordon S.B., Chaponda M., Walsh A.L., Whitty C.J., Gordon M.A., Machili C.E., et al. Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival. AIDS 16 July (10) (2002) 1409-1417
7. Casal J., and Tarrago D. Immunity to Streptococcus pneumoniae: factors affecting production and efficacy. Curr Opin Infect Dis 16 June (3) (2003) 219-224
8. McEllistrem M.C., Mendelsohn A.B., Pass M.A., Elliott J.A., Whitney C.G., Kolano J.A., et al. Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection. J Infect Dis 185 May (9) (2002) 1364-1368
9. Griffith F. The significance of pneumococcal types. J Hyg (Lond) 27 (1928) 113-159
10. Gordon S.B., Miller D.E., Day R.B., Ferry T., Wilkes D.S., Schnizlein-Bick C.T., et al. Pulmonary immunoglobulin responses to Streptococcus pneumoniae are altered but not reduced in human immunodeficiency virus-infected Malawian adults. J Infect Dis 188 September (5) (2003) 666-670
11. Austrian R. Maxwell finland lecture. Random gleanings from a life with the pneumococcus. J Infect Dis 131 (1975) 474-484
12. Austrian R. Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines. J Infect Dis 136 August (Suppl) (1977) S38-S42
13. Temple K., Greenwood B., Inskip H., Hall A., Koskela M., and Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in African children. Pediatr Infect Dis J 10 May (5) (1991) 386-390
14. French N., Nakiyingi J., Carpenter L.M., Lugada E., Watera C., Moi K., et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 355 June (9221) (2000) 2106-2111
15. French N. Use of pneumococcal polysaccharide vaccines: no simple answers. J Infect 46 February (2) (2003) 78-86
16. Simberkoff M.S., Cross A.P., Al-Ibrahim M., Baltch A.L., Geiseler P.J., Nadler J., et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 315 November (21) (1986) 1318-1327
17. Jackson L.A., Neuzil K.M., Yu O., Benson P., Barlow W.E., Adams A.L., et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 348 May (18) (2003) 1747-1755
18. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 May (18) (2003) 1737-1746
19. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., and Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 October (14) (2003) 1341-1348
20. Cutts F.T., Zaman S.M.A., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-bline, placebo-controlled trial. Lancet 365 (2005) 1139-1146
21. Whitney C.G., and Pickering L.K. The potential of pneumococcal conjugate vaccines for children. Pediatr Infect Dis J 21 October (10) (2002) 961-970
22. Out T.A., Wang S.Z., Rudolph K., and Bice D.E. Local T-cell activation after segmental allergen challenge in the lungs of allergic dogs. Immunology 105 April (4) (2002) 499-508
23. Bice D.E., and Muggenburg B.A. Pulmonary immune memory: localized production of antibody in the lung after antigen challenge. Immunology 88 June (2) (1996) 191-197
24. Gordon SB, Kayhty H, Molyneux ME, Haikala R, Nurkka A, Musaya J, et al. Pneumococcal conjugate vaccine is immunogenic in lung fluid of HIV-infected and immunocompetent adults. J Allergy Clin Immunol; 2007 (June 1).
25. Eagan R., Twigg III H.L., French N., Musaya J., Day R.B., Zijlstra E.E., et al. Lung fluid immunoglobulin from HIV-infected subjects has impaired opsonic function against pneumococci. Clin Infect Dis 44 June (12) (2007) 1632-1638
26. Menzel M., Muellinger B., Weber N., Haeussinger K., and Ziegler-Heitbrock L. Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers. Vaccine 23 October (43) (2005) 5113-5119
27. Meyer P., Menzel M., Muellinger B., Weber N., Haeussinger K., and Ziegler-Heitbrock L. Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease. Vaccine 24 July (31/32) (2006) 5832-5838
28. Haugaard L., Iversen M., and Dahl R. A comparative study of four different bronchial challenge tests. Allergy 47 April (2 Pt 2) (1992) 138-142
29. Gordon S.B., Molyneux M.E., Boeree M.J., Kanyanda S., Chaponda M., Squire S.B., et al. Opsonic phagocytosis of Streptococcus pneumoniae by alveolar macrophages is not impaired in human immunodeficiency virus-infected Malawian adults. J Infect Dis 184 November (10) (2001) 1345-1349
30. Dennis J.H. A review of issues relating to nebulizer standards. J Aerosol Med 11 Suppl 1 (1998) S73-S79
31. Wernette C.M., Frasch C.E., Madore D., Carlone G., Goldblatt D., Plikaytis B., et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 10 July (4) (2003) 514-519
32. Musher D.M., Luchi M.J., Watson D.A., Hamilton R., and Baughn R.E. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis 161 April (4) (1990) 728-735
33. Rusznak C., Sapsford R.J., Devalia J.L., Shah S.S., Hewitt E.L., Lamont A.G., et al. Interaction of cigarette smoke and house dust mite allergens on inflammatory mediator release from primary cultures of human bronchial epithelial cells. Clin Exp Allergy 31 February (2) (2001) 226-238
34. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine [see comments]. N Engl J Med 325 21 (1991) 1453-1460
35. Malley R., Trzcinski K., Srivastava A.K., Thompson C.M., Anderson P.W., and Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 102 13 (2005) 4848-4853
36. Weiser J.N., Bae D., Fasching C., Scamurra R.W., Ratner A.J., and Janoff E.N. Antibody-enhanced pneumococcal adherence requires IgA1 protease. Proc Natl Acad Sci USA 100 April (7) (2003) 4215-4220
37. Weiser J.N., Markiewicz Z., Tuomanen E.I., and Wani J.H. Relationship between phase variation in colony morphology, intrastrain variation in cell wall physiology, and nasopharyngeal colonization by Streptococcus pneumoniae. Infect Immun 64 June (6) (1996) 2240-2245
38. Weiser J.N., Bae D., Epino H., Gordon S.B., Kapoor M., Zenewicz L.A., et al. Changes in availability of oxygen accentuate differences in capsular polysaccharide expression by phenotypic variants and clinical isolates of Streptococcus pneumoniae. Infect Immun 69 September (9) (2001) 5430-5439
39. Gordon S.B., Irving G.R., Lawson R.A., Lee M.E., and Read R.C. Intracellular trafficking and killing of Streptococcus pneumoniae by human alveolar macrophages are influenced by opsonins. Infect Immun 68 April (4) (2000) 2286-2293
40. McNeely T.B., and Coonrod J.D. Comparison of the opsonic activity of human surfactant protein A for Staphylococcus aureus and Streptococcus pneumoniae with rabbit and human macrophages. J Infect Dis 167 January (1) (1993) 91-97
41. Jonsson S., Musher D.M., Chapman A., Goree A., and Lawrence E.C. Phagocytosis and killing of common bacterial pathogens of the lung by human alveolar macrophages. J Infect Dis 152 1 (1985) 4-13
42. Hof D.G., Repine J.E., Giebink G.S., and Hoidal J.R. Production of opsonins that facilitate phagocytosis of Streptococcus pneumoniae by human alveolar macrophages or neutrophils after vaccination with pneumococcal polysaccharide. Am Rev Respir Dis 124 (1981) 193-195
43. Gordon S.B., and Read R.C. Macrophage defences against respiratory tract infections. Br Med Bull 61 (2002) 45-61
44. Nuorti J.P., Butler J.C., Gelling L., Kool J.L., Reingold A.L., and Vugia D.J. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 132 February (3) (2000) 182-190
45. Boyton R.J., and Openshaw P.J. Pulmonary defences to acute respiratory infection. Br Med Bull 61 (2002) 1-12
46. Knapp S., Leemans J.C., Florquin S., Branger J., Maris N.A., Pater J., et al. Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 167 January (2) (2003) 171-179
47. Bogaert D., de Groot R., and Hermans P.W. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4 March (3) (2004) 144-154
48. Briles D.E., Hollingshead S., Brooks-Walter A., Nabors G.S., Ferguson L., Schilling M., et al. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 18 February (16) (2000) 1707-1711